🇺🇸

US SEC Filing Intelligence

· daily

Contract Option Exercises — May 18, 2026

The two contracts awarded on May 15, 2026, total $605.6 million in obligations, with zero defense-related awards — both are civilian agency contracts (DHS and HHS), highlighting a bifurcated government spending pattern. The dominant signal is a $605 million DHS/CBP border wall construction award to private firm Fisher Sand & Gravel, which, while not directly investable, signals sustained infrastructure spending that could benefit publicly traded subcontractors or material suppliers. The second award, a $542,604 HHS/ASPR sterile water contract to Pfizer, is immaterial to the company's $60B+ revenue base. The highest-conviction signal is the border wall contract's full competition after exclusion of sources, which introduces execution and political risk. Key watch items include potential subcontractor disclosures from Fisher Sand & Gravel and DHS budget appropriations for border security.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — May 18, 2026

The single mega-contract in this period is a $605M firm-fixed-price delivery order from DHS/CBP to privately held Fisher Sand & Gravel for border wall construction in San Diego. This is a purely civilian award with no defense exposure, signaling sustained government investment in border infrastructure under a full-and-open competition structure. The neutral signal strength (5/10) and lack of public equity direct exposure limit immediate investment implications, but the contract's size and fixed-price risk profile warrant monitoring for subcontractor or material supplier disclosures. Key risks include execution cost overruns on the fixed-price contract and potential budget or policy shifts affecting border wall appropriations.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 18, 2026

The single high-value grant analyzed for May 18, 2026, is a $605M firm-fixed-price delivery order from the Department of Homeland Security (DHS/CBP) to privately held Fisher Sand & Gravel for border wall construction in San Diego. This is a civilian contract with no direct defense exposure, and the neutral signal strength (5/10) reflects the lack of publicly traded prime exposure. The award underscores sustained government investment in border infrastructure, but execution risk is high given the fixed-price nature and political sensitivity. Key watch items include potential subcontractor disclosures and DHS budget appropriations for border security.

1 total filings
· daily

General Federal Contracts — May 18, 2026

This single-contract digest reveals a $605M civilian award from the Department of Homeland Security (DHS) to Fisher Sand & Gravel for border wall construction in San Diego, representing 100% of the period's total obligation. The contract is entirely civilian (0% defense-related) and carries a neutral signal strength of 5/10, reflecting the lack of direct public equity exposure due to the recipient's private status. The highest-conviction signal is the sustained government investment in border infrastructure, which may indirectly benefit publicly traded material suppliers or subcontractors. Key risks include execution risk from the firm-fixed-price structure and potential political volatility around border wall funding, particularly under a continuing resolution scenario.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 18, 2026

The 17 filings reveal a mixed landscape within the S&P 500 Technology sector and broader market. Key themes include significant insider buying at Genco Shipping, a large jury verdict against Acadia Healthcare, and a forward stock split for the abrdn Palladium ETF. Period-over-period trends show Genco's dramatic turnaround to profitability, while Madison Technologies remains revenue-less with worsening cash burn. Insider activity is sparse but notable at Genco, where management is actively opposing a tender offer. Capital allocation varies, with Genco increasing dividends and Cottonwood raising preferred equity. Forward-looking data highlights upcoming catalysts such as ImmunityBio's FDA engagement for BCG approval and RideNow's potential credit facility expansion. Overall, the digest points to selective opportunities in shipping and biotech, while caution is warranted for cash-burning microcaps and litigation risks.

6 high priority 11 medium 17 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 18, 2026

The 18 filings reveal a bifurcated landscape: while Genco Shipping & Trading and CoStar Group show strong operational turnarounds and proactive capital allocation, several biotech and cash-burning companies (Estrella Immunopharma, Madison Technologies) face liquidity pressures. Period-over-period comparisons highlight Genco's net income swing of +$21.2M YoY and CoStar's $1.5B buyback authorization, contrasting with Estrella's 28.5% G&A surge and Madison's zero revenue. Insider activity is limited but notable: Genco's CEO actively defends against a tender offer, while Acadia Healthcare faces a $105M adverse verdict. Forward-looking catalysts include MetaVia's ADA abstracts and ImmunityBio's BCG approval path. Sector themes center on capital discipline (shipping, real estate) versus speculative biotech spending, with a cautious tech hedge evidenced by Arkadios Wealth Advisors' large QQQ put positions.

5 high priority 13 medium 18 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 18, 2026

The May 18, 2026 batch of 50 S&P 500 Financials filings reveals a sector bifurcated between large-cap stability and small/mid-cap distress. The most significant event is the $2.5B all-cash acquisition of LiveRamp by Publicis Groupe at a 30% premium, signaling strong M&A appetite for data assets. However, this is overshadowed by severe distress signals: Bitcoin Depot has entered bankruptcy proceedings, and Gossamer Bio is executing a coercive debt-for-equity swap requiring 98% participation. Period-over-period trends show a mixed picture: LiveRamp's 9% YoY revenue growth and 107% net retention contrast sharply with iSpecimen's 85% revenue collapse and OLB Group's 29% decline. Insider activity is notably absent across most filings, but management actions—such as Wyndham's CEO disclosing a cancer diagnosis while reaffirming guidance—provide nuanced signals. Capital allocation trends are defensive: Coeur Mining has aggressively repurchased $69.7M of stock, while Presidio Property Trust is cutting debt and CEO pay. The overarching theme is capital preservation and strategic repositioning, with M&A and restructuring dominating the narrative over organic growth.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 18, 2026

The 50 filings for the S&P 500 Consumer Staples stream reveal a sector in transition, with significant capital allocation shifts, governance battles, and a few high-growth outliers. While the majority of filings are procedural (annual meeting results, proxy statements), several high-materiality events stand out. **Altria Group** faces a high-risk director departure, while **CoStar Group** is undertaking a major governance and capital allocation overhaul in response to activist pressure, including a $1.5B buyback. **CleanCore Solutions** presents a significant red flag with a material restatement and internal control weakness, contrasting with **Koil Energy Solutions** which reported record revenue and a return to profitability. **Claritev Corp** disclosed a DOJ antitrust probe, adding regulatory risk. The most actionable themes are the push for shareholder-friendly capital returns (CoStar, CCEP) and the severe financial reporting issues at CleanCore, which serve as a cautionary tale for micro-cap investors. Overall, the sector shows a mix of stable, cash-generating businesses returning capital and smaller players facing existential challenges.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 18, 2026

The 50 filings from the S&P 500 Industrials stream reveal a sector bifurcated between robust growth in niche areas (e.g., shipping, medical devices) and significant financial distress in others (e.g., Bitcoin Depot's Bitcoin Depot's bankruptcy, Banzai's dilution). Period-over-period data shows strong revenue growth at Bally's (+28.3% YoY) and Genco Shipping (swinging to a $9.3M profit from an $11.9M loss), but also highlights margin compression and cash burn at several firms. Insider activity is limited, but the heavy insider-related financing at Yale Transaction Finders and the departure of FedEx's CAO are notable. Capital allocation trends are mixed, with Bally's refinancing debt and Genco raising dividends, while others like Tofutti Brands and ABVC Biopharma face severe cash constraints. The most critical developments include Bitcoin Depot's bankruptcy, Bally's major project advancements, and the FedEx Freight spin-off, which together signal a 'survival of the fittest' dynamic in the industrials space.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 18, 2026

The three filings for the S&P 500 Energy stream on May 18, 2026, represent a very quiet session with no direct energy sector activity. The primary developments are procedural steps in XOMA Royalty Corp's merger with Ligand Pharmaceuticals, involving a holding company reorganization that does not alter economic terms. Chesapeake Wealth Management's 13F filing provides a snapshot of a diversified portfolio with no energy-specific concentration. No period-over-period comparisons, insider trading, forward-looking guidance, or capital allocation changes were present in any of the filings, limiting actionable insights. The absence of energy sector filings and the lack of enriched data trends (e.g., revenue growth, margin changes) indicate a lull in sector activity. Investors should monitor for upcoming earnings calls and regulatory decisions from major energy companies to identify future catalysts.

1 high priority 2 medium 3 total filings
· daily

US Material Events SEC 8-K Filings — May 18, 2026

The May 18, 2026, filing cycle reveals a market bifurcated between aggressive capital deployment and acute financial distress. The dominant themes are a wave of equity and debt financing (Akamai, Babcock & Wilcox, Ideal Power, Old Republic) aimed at funding growth and strategic initiatives, contrasted with a high-profile bankruptcy at Bitcoin Depot and a major acquisition of LiveRamp by Publicis. Leadership transitions are widespread, with several companies (Flagstar, NextEra Energy, T. Rowe Price) executing planned successions, while others (Wyndham, CVS Health) face unexpected changes. A notable trend is the use of convertible notes and equity facilities, which provide capital but introduce dilution risks. The healthcare sector shows significant positive activity, with ImmunityBio and Context Therapeutics advancing key pipeline assets. Overall, the data suggests a market where well-capitalized firms are aggressively pursuing growth, while others are restructuring or facing existential challenges.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 18, 2026

The May 18, 2026 batch of 50 filings from the Dow 30 universe reveals a market bifurcated between aggressive capital deployment and operational strain. A dominant theme is the use of equity-linked financing and M&A to fund growth, with notable examples including LiveRamp's $2.5B all-cash acquisition by Publicis Groupe at a 30% premium, Bally's $4.0B Bronx development and $1.1B refinancing, and Soluna's $53M wind farm acquisition. However, this expansion is occurring against a backdrop of widening losses and cash burn for many companies, as seen in Soluna's net loss doubling to $17.9M and ABVC Biopharma's 79% loss increase with zero revenue. Insider activity is sparse but notable, with director resignations at Innoviva and significant shareholder dissent on pay at Nicolet Bankshares (32.7% against). Capital allocation is mixed: while some firms like Virgin Galactic are using stock to pay down debt, others like Babcock & Wilcox are raising $200M via dilutive offerings. The forward-looking calendar is rich with catalysts, including the July 6, 2026 Clough fund meetings and the May 19, 2026 NBT Bancorp annual meeting, but also carries risks from pending regulatory approvals (CFIUS on LiveRamp) and ongoing Nasdaq compliance issues (Faraday Future). Overall, the data suggests a market where strategic bets are being placed, but the financial health of the underlying companies requires close scrutiny of cash flow and margin trends.

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 18, 2026

Today's filings reveal a bifurcated market: robust M&A activity (LiveRamp acquisition at 30% premium, Artivion's $175M Endospan buy) contrasts with severe distress signals (Bitcoin Depot bankruptcy, Gossamer Bio restructuring). Revenue trends are mixed—LiveRamp (+9% YoY) and Coeur Mining's buyback execution show strength, while iSpecimen (-85% revenue decline) and OLB Group (-28.6%) highlight micro-cap fragility. Insider activity is sparse but notable: Wyndham CEO's health disclosure introduces leadership uncertainty. Capital allocation patterns diverge sharply—CoreCivic's buyback program contrasts with Perma-Fix's dilutive offering. Sector themes include consolidation in building products (QXO/TopBuild), biotech restructuring (Gossamer Bio, Context Therapeutics), and crypto-exposed portfolios (SkyBridge's 97% Bitcoin concentration). The catalyst calendar features LiveRamp shareholder vote, Gossamer Bio exchange offer deadline, and Context Therapeutics' Phase 1 trial initiation.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 18, 2026

The 50 filings from the S&P 500 Consumer Discretionary sector reveal a sector in transition, marked by aggressive capital restructuring, significant insider activity, and a clear bifurcation between companies investing for growth and those facing operational headwinds. A dominant theme is the use of high-cost debt and equity-linked financing, with Wayfair issuing $400M in 7.125% notes and Faraday Future securing $70M in convertible notes, signaling elevated borrowing costs and potential dilution. Insider trading patterns are a key signal, with the CEO of Fermi Inc. ousted for cause and a proxy battle underway, while O'Reilly Automotive's board approved a $2M stock option for its executive chairman, indicating confidence. Period-over-period data shows mixed performance: Fatpipe Inc. grew revenue 17.9% YoY but saw operating cash flow turn negative, while Tofutti Brands saw sales decline 2.1% and losses widen. Capital allocation is a key differentiator, with InfuSystem announcing a $20M buyback and O'Reilly maintaining shareholder returns, contrasting with the dilutive financing at Flux Power and Profusa. The most critical development is the $1.5B MiRus investment by Boston Scientific, a bold bet on the TAVR market, while the ongoing proxy fight at Fermi Inc. and the short-term forbearance at FiscalNote highlight governance and liquidity risks. Overall, the sector shows a 'haves and have-nots' dynamic, where strong balance sheets are being used for strategic M&A and buybacks, while weaker players are forced into costly financing and face shareholder activism.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 18, 2026

The 45 filings for the S&P 500 Healthcare sector reveal a sector in transition, marked by aggressive M&A (Neurocrine's $2.9B Soleno deal, Boston Scientific's $B MiRus investment) and significant capital allocation shifts (Bally's refinancing, CoreWeave's $B AI infrastructure debt). Period-over-period data shows a stark divergence: medical device and specialty pharma companies are posting strong growth (Catheter Precision +202% YoY, Bally's +28%), while diagnostics and smaller biotechs face severe revenue declines (iSpecimen -85% YoY). Insider activity is mixed, with notable director departures at Medtronic and CVS, but also new appointments at Flagstar Bank and Cellectar. Forward-looking data highlights a busy catalyst calendar with upcoming FDA decisions, shareholder votes, and clinical trial readouts. Capital allocation trends show a preference for debt-funded M&A and share buybacks, with several companies (Webster, CCEP) facing governance scrutiny over deal terms and executive compensation. Overall, the sector is experiencing a 'barbell' effect where large-cap players are consolidating and investing in high-growth areas (AI, gene therapy, TAVR), while smaller players struggle with cash burn and operational challenges.

15 high priority 30 medium 45 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 18, 2026

This batch of 10 proxy filings reveals a mixed landscape for the 2026 annual meeting season, with the season, with the most actionable intelligence concentrated in T1 Energy's aggressive growth plans and Flag Ship Acquisition's existential deadline. T1 Energy stands out with strong first-year operational results—2.79 GW of solar modules manufactured and $755.3 million in net sales—but the proposal to double authorized shares from 500 million to 1 billion creates significant dilution risk for existing holders. The three Clough funds (GLQ, GLO, GLV, GLO) are purely procedural, offering no financial data or compensation insights, while Braze and SmartKem provide governance and committee activity details without quantitative performance metrics. Flag Ship Acquisition Corp presents a binary event: if the extension proposal fails, the SPAC will liquidate by June 20, 2026, rendering public rights worthless. Snowflake's Creations shows a board reduction from six to five members as Shirley Romig steps down, signaling potential governance streamlining. Overall, the lack of enriched period-over-period data in most filings limits trend analysis, but the few actionable filings that do contain operational data point to capital-intensive growth strategies and governance scrutiny as key themes for the June-July 2026 meeting window.

10 high priority 10 total filings
· daily

Global High-Priority Regulatory Events — May 18, 2026

The May 18, 2026 filing stream reveals a market bifurcated between aggressive strategic consolidation and acute financial distress. The most dominant theme is a wave of transformative M&A, led by NextEra Energy's $38B+ bid for Dominion Energy and Publicis Groupe's $2.5B acquisition of LiveRamp acquisition signal a high-conviction bet on scale in-sector consolidation and data infrastructure, respectively. However, this bullish activity is sharply contrasted by severe distress signals: Bitcoin Depot has entered bankruptcy, MTNL has disclosed a massive ₹9,339 Cr default, and several micro-cap biote-stage biotechs (ABVC, iSpecimen) are burning cash with no revenue. Period-over-period data shows a stark divergence, with LiveRamp growing revenue 9% YoY and achieving record cash flow, while OLB Group and iSpecimen saw revenues collapse 28.6% and 85.2% YoY, respectively. Insider activity ispersed across these extremes, we see tactical capital deployment via buybacks (CMS Info Systems) and insider-driven moves (TVS Motor's strategic bank stake), alongside a flurry of regulatory and insolvency proceedings in India, indicating a market that is aggressively pricing in both future growth and imminent failure.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 18, 2026

The 27 filings reveal a stark bifurcation in the US micro-cap landscape: revenue growth is concentrated in a few outliers (CBAK Energy +99%, Hyperscale Data + Bally's Corp + Catheter Precision), while the majority of filers show revenue declines, zero revenue, or zero revenue with zero revenue. Period-over-period data shows aggregate revenue for the 27 filers fell ~15% YoY, with 14 of 27 reporting lower or zero revenue. Margin compression is severe—CBAK Energy's gross profit collapsed 78% despite revenue doubling, and NanoVibronix swung to a gross loss. Insider activity is absent in most filings, but capital allocation signals distress: 8 companies have zero cash, 5 are funding operations solely via related-party loans, and dilution is rampant (NanoVibronix shares outstanding surged 236% in one quarter). Forward-looking data is sparse, but scheduled events (earnings calls) for Bally's Corp and Hyperscale Data offer near-term catalysts. The most actionable themes are the 'cash-zero' cohort (6 companies with zero cash) and the 'revenue growth vs. margin destruction' trade-off in CBAK Energy and Hyperscale Data.

27 high priority 27 total filings
· daily

US SEC Trading Suspension Halt Orders — May 18, 2026

Two regulatory filings on May 18, 2026 highlight contrasting listing statuses: Palatin Technologies voluntarily delists from NYSE American to transfer to Nasdaq Capital Market, maintaining its symbol PTN, while Synergy CHC Corp. faces a Nasdaq deficiency notice for failing to maintain the $1.00 bid price, with a 180-day cure period until November 11, 2026. Palatin's move is neutral, reflecting a strategic exchange transfer without financial impact, whereas Synergy's situation is negative, signaling potential delisting risk. No period-over-period comparisons, insider transactions, or forward-looking guidance were provided in either filing, limiting trend analysis. The key takeaway is the divergence in exchange health: one company proactively upgrades, the other struggles to meet listing standards. Investors should monitor Synergy's compliance efforts, including a possible reverse stock split, and Palatin's Nasdaq debut for liquidity changes.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 18, 2026

The May 18, 2026, filing batch reveals a bifurcated corporate landscape: while several companies are executing strategic growth moves (e.g., CoreWeave's $3.1B oversubscribed AI infrastructure financing, LiveRamp's acquisition at a 30% premium), a significant cohort is exhibiting acute financial distress. The most critical signal is Bitcoin Depot's bankruptcy filing (Item 1.03), representing a total equity wipeout for shareholders. This is compounded by a wave of dilutive equity financings (Ideal Power, Babcock & Wilcox, Faraday Future) and covenant-laden credit amendments (Inotiv, Zevia) that signal liquidity stress. A notable pattern is the surge in capital markets activity, with $4.8B+ in new debt and equity issuance across just 10 filings, indicating companies are aggressively pre-funding or restructuring ahead of potential market turbulence. Insider trading data is sparse, but the absence of insider buying during these dilutive events is a bearish signal. The overarching theme is a 'flight to quality' where well-capitalized firms (CoreWeave, NextEra) access favorable terms, while distressed names (Bitcoin Depot, Inotiv) face punitive financing and existential risk.

50 high priority 50 total filings